Portal de Periódicos da CAPES

Vasoactive Intestinal Polypeptide (VIP) in Asthma a

1991; Wiley; Volume: 629; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.1991.tb37985.x

1749-6632

Sami I. Said,

Diabetes Treatment and Management

Annals of the New York Academy of SciencesVolume 629, Issue 1 p. 305-318 Vasoactive Intestinal Polypeptide (VIP) in Asthmaa SAMI I. SAID, SAMI I. SAID Department of Medicine (MIC 789) University of Illinois at Chicago College of Medicine and West Side Veterans Affairs Medical Center 1940 West Taylor Street Chicago, Illinois 60612Search for more papers by this author SAMI I. SAID, SAMI I. SAID Department of Medicine (MIC 789) University of Illinois at Chicago College of Medicine and West Side Veterans Affairs Medical Center 1940 West Taylor Street Chicago, Illinois 60612Search for more papers by this author First published: July 1991 https://doi.org/10.1111/j.1749-6632.1991.tb37985.xCitations: 47 a Supported by National Institutes of Health Grant HL-30450 and by the Department of Veterans Affairs. S.I.S. is a Medical Investigator of the V.A. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Piper, P. J., S. I. Said & J. R. Vane. 1970. Effects on smooth muscle preparations of unidentified vasoactive peptides from the intestine and lung. Nature 225: 1144–1146. 10.1038/2251144a0 CASPubMedWeb of Science®Google Scholar 2 Said, S. I., S. Kitmatura, T. Yoshida, J. Preskitt & L. D. Holden. 1974. Humoral control of airways. Ann. N.Y. Acad. Sci. 221: 103–114. 10.1111/j.1749-6632.1974.tb28205.x CASPubMedWeb of Science®Google Scholar 3 Wasserman, M. A., R. L. Griffin & P. E. Malo. 1982. Comparative in vitro tracheal-relaxant effects of porcine and hen VIP. In Vasoactive Intestinal Peptide. S. I. Said, Ed.: 177–184. Raven Press. New York . Google Scholar 4 Ito, Y. & K. Takeda. 1982. Non-adrenergic inhibitory nerves and putative transmitters in the smooth muscle of cat trachea. J. Physiol. 330: 497–511. 10.1113/jphysiol.1982.sp014355 CASPubMedWeb of Science®Google Scholar 5 Cameron, A. C., C. F. Johnson, C. T. Kirkpatrick & M. C. A. Kirkpatrick. 1983. The quest for the inhibitory neurotransmitter in bovine tracheal smooth muscle. Quart. J. Exp. Physiol. 68: 413–426. 10.1113/expphysiol.1983.sp002735 CASPubMedWeb of Science®Google Scholar 6 Hamasaki, Y., T. Saga, M. Mojarad & S. I. Said. 1983. VIP counteracts leukotriene D4-induced contractions of guinea pig trachea, lung, and pulmonary artery. Trans. Assoc. Am. Physicians 96: 406–411. CASPubMedWeb of Science®Google Scholar 7 Said, S. I. Influence of neuropeptides on airway smooth muscle. 1987. Am. Rev. Respir. Dis. 136 (Suppl.): S5258. Google Scholar 8 Said, S. I. Vasoactive intestinal peptide in the lung. 1988. Ann. NY Acad. Sci. 527: 450–464. 10.1111/j.1749-6632.1988.tb26999.x CASPubMedWeb of Science®Google Scholar 9 Boomsma, J. D., H. D. Foda & S. I. Said. 1990. Vasoactive intestinal peptide (VIP) reverses endothelin-induced contractions of guinea pig trachea and pulmonary artery. Am. Rev. Respir. Dis. 141: A485. Google Scholar 10 Altiere, R. J. & L. Diamond. 1984. Comparison of vasoactive intestinal peptide and isoproterenol relaxant effects in isolated cat airways. J. Appl. Physiol. 56: 986. CASPubMedWeb of Science®Google Scholar 11 Hand, J. M., R. B. Laravuso & J. A. Will. 1984. Relaxation of isolated guinea pig trachea, bronchi and pulmonary arteries produced by vasoactive intestinal peptide (VIP). Eur. J. Pharmacol. 9: 279–284. 10.1016/0014-2999(84)90602-2 Web of Science®Google Scholar 12 Saga, T. & S. I. Said. 1984. Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans. Assoc. Am. Physicians 97: 304–310. CASPubMedWeb of Science®Google Scholar 13 Said, S. I., A. Geumei & N. Hara. 1982. Bronchodilator effect of VIP in vivo: protection against bronchoconstriction induced by histamine or prostaglandin F2α. In Vasoactive Intestinal Peptide. S. I. Said, Ed.: 185–191. Raven Press. New York . Google Scholar 14 Cox, C. P., M. R. Lerner, J. J. Wells & S. I. Said. 1983. Inhaled vasoactive intestinal peptide (VIP) prevents bronchoconstriction induced by inhaled histamine. Am. Rev. Respir. Dis. 127: 249. Web of Science®Google Scholar 15 Diamond, L., J. L. Szarek, M. N. Gillespie & R. J. Altiere. 1983. In vivo bronchodilator activity of vasoactive intestinal peptide in the cat. Am. Rev. Respir. Dis. 128: 827–832. CASPubMedWeb of Science®Google Scholar 16 Uddman, R. & F. Sundler. 1979. VIP nerves in human upper respiratory tract. Otorhinolaryngology 41: 221–226. CASPubMedWeb of Science®Google Scholar 17 Dey, R. D., W. A. Shannon & S. I. Said. 1981. Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cats and human subjects. Cell Tissue Res. 220: 231–238. 10.1007/BF00210505 CASPubMedWeb of Science®Google Scholar 18 Laitinen, A., M. Partanen, A. Hervonen, M. Pelto-Huikko & L. A. Laitenen. 1985. VIP-like immunoreactive nerves in human respiratory tract. Histochemistry 82: 313–319. 10.1007/BF00494059 CASPubMedWeb of Science®Google Scholar 19 Uddman, R., A. Luts & F. Sundler. 1985. Nerve fibres containing peptide histidine isoleucine (PIH) in the respiratory tract. Arch. Otorhinolaryngol. 242: 189–193. 10.1007/BF00454420 CASPubMedWeb of Science®Google Scholar 20 Dey, R. D., T. Shimosegawa & S. I. Said. Lung peptides and the pulmonary circulation. In The Pulmonary Circulation and Acute Lung Injury, 2nd Edit. S. I. Said, Ed. Futura Publishing Co. New York . In press. Google Scholar 21 Cutz, E., W. Chan, N. S. Track, A. Goth & S. I. Said. 1978. Release of vasoactive intestinal polypeptide in mast cells by histamine liberators. Nature 275: 661–662. 10.1038/275661a0 CASPubMedWeb of Science®Google Scholar 22 Goetzl, E. J., S. P. Sreedharan & C. W. Turck. 1988. Structurally distinctive vasoactive intestinal peptides from rat basophilic leukemia cells. J. Biol. Chem. 263: 9083–9086. CASPubMedWeb of Science®Google Scholar 23 Itoh, N., K. Obata, N. Yanaihara & H. Okamoto. 1983. Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27. Nature 304: 541–549. 10.1038/304547a0 PubMedWeb of Science®Google Scholar 24 Lundberg, J. M., A. ÄNggård, J. Fahrenkrug, T. Hökfelt & V. Mutt. 1980. Vasoactive intestinal polypeptide in cholinergic neurons of exocrine glands: functional significance of co-existing transmitters for vasodilation and secretion. Proc. Natl. Acad. Sci. USA 77: 1651–1655. 10.1073/pnas.77.3.1651 CASPubMedWeb of Science®Google Scholar 25 Shimosegawa, T., H. D. Foda & S. I. Said. 1990. [Met]enkephalin-arg6-gly7-leu8-immunoreactive nerves in guinea-pig and rat lungs: distribution, origin, and coexistence with vasoactive intestinal polypeptide immunoreactivity. Neuroscience 36: 737–750. 10.1016/0306-4522(90)90016-W PubMedWeb of Science®Google Scholar 26 Dey, R. D., J. Hoffpauir & S. I. Said. 1988. Co-localization of vasoactive intestinal peptide- and substance P-containing nerves in cat bronchi. Neuroscience 24: 275–281. 10.1016/0306-4522(88)90330-2 CASPubMedWeb of Science®Google Scholar 27 Schaffer, M. M., D. N. Carney, L. Y. Korman, G. S. Lebovic & T. W. Moody. 1987. High affinity binding of VIP to human lung cancer cell lines. Peptides 8: 1101–1106. 10.1016/0196-9781(87)90143-4 PubMedWeb of Science®Google Scholar 28 Luis, J. & S. I. Said. 1990. Characterization of VIP- and helodermin-preferring receptors on human small cell lung carcinoma cell lines. Peptides 11: 1239–1244. 10.1016/0196-9781(90)90158-2 CASPubMedWeb of Science®Google Scholar 29 Bitar, K. N. & G. M. Makhlouf. 1982. Relaxation of isolated gastric smooth muscle cells by vasoactive intestinal peptide. Science 216: 531–533. 10.1126/science.6176025 CASPubMedWeb of Science®Google Scholar 30 Huang, M. & O. P. Rorstad. 1983. Effects of vasoactive intestinal polypeptide, monoamines, prostaglandins, and 2-chloradenosine on adenylate cyclase in rat cerebral microvessels. J. Neurochem. 40: 719–726. 10.1111/j.1471-4159.1983.tb08038.x CASPubMedWeb of Science®Google Scholar 31 Amiranhoff, B. & G. Rosselin. 1982. VIP receptors and control of cyclic AMP production. In Vasoactive Intestinal Peptide. S. I. Said, Ed.: 307–322. Raven Press, New York . Google Scholar 32 Frandsen, E. K., G. A. Krishna & S. I. Said. 1978. Vasoactive intestinal polypeptide promotes cyclic adenosine 3′,5′-monophosphate accumulation in guinea pig trachea. Br. J. Pharmacol. 62: 367–369. 10.1111/j.1476-5381.1978.tb08471.x CASPubMedWeb of Science®Google Scholar 33 Kitamura, S., Y. Ishihara & S. I. Said. 1980. Effect of VIP, phenoxybenazamine and prednisolone on cyclic nucleotide content of isolated guinea-pig lung and trachea. Eur. J. Pharmacol. 67: 219–223. 10.1016/0014-2999(80)90501-4 CASPubMedWeb of Science®Google Scholar 34 Taton, G., M. Delhaye, J.-C. Camus, P. De Neef, P. Chatelain, P. Robberecht & J. Christophe. 1981. Characterization of the VIP- and secretin-stimulated adenylate cyclase system from human lung. Pflugers Arch. 391: 178–182. 10.1007/BF00596167 CASPubMedWeb of Science®Google Scholar 35 Gozes, I. & D. E. Brenneman. 1989. VIP: molecular biology and neurobiological function. Molec. Neurobiol. 3: 201–236. 10.1007/BF02740606 CASPubMedWeb of Science®Google Scholar 36 Lazarus, S. C., C. B. Basbaum, P. J. Barnes & W. M. Gold. 1986. Mapping of VIP receptors by use of an immunocytochemical probe for the intracellular mediator cyclic AMP. Am. J. Physiol. 251: C115–119. CASPubMedWeb of Science®Google Scholar 37 Leroux, P., H. Vaudry, A. Fournier, S. St.-Pierre & G. Pelletier. 1984. Characterization and localization of vasoactive intestinal peptide receptors in the rat lung. Endocrinology 114: 1506–1512. 10.1210/endo-114-5-1506 CASPubMedWeb of Science®Google Scholar 38 Carstairs, J. R. & P. J. Barnes. 1986. Autoradiographic mapping of substance P receptors in lung. Eur. J. Pharmacol. 127: 295–296. 10.1016/0014-2999(86)90380-8 PubMedWeb of Science®Google Scholar 39 Carstairs, J. R. & P. J. Barnes. 1986. Visualization of vasoactive intestinal peptide receptors in human and guinea pig lung. J. Pharmacol. Exp. Ther. 239: 249–255. CASPubMedWeb of Science®Google Scholar 40 Said, S. I. & R. D. Dey. 1988. VIP in the airways. In The Airways: Neural Control in Health and Disease. M. A. Kaliner & P. Branes, Eds.: 395–416. In Lung Biology in Health and Disease. C. Lenfant, Exec. Ed. Marcel Dekker. New York. Google Scholar 41 Sakakibara, H., K. Shima & S. I. Said. 1990. Vasoactive intestinal polypeptide (VIP) binds to cultured bronchial epithelial cells derived from normal rhesus monkey (4MBr-5). Clin. Res. 38: 824A. Google Scholar 42 Sakakibara, H., K. Shima, Y. Lin & S. I. Said. 1990. Binding of vasoactive intestinal polypeptide (VIP) to rat alveolar macrophages: demonstration of specific binding sites coupled to adenylate cyclase. Am. Rev. Respir. Dis. 141: A645. Google Scholar 43 Luis, J. J.-M. Muller, B. Abadie, J.-M. Martin, J. Marvaldi & J. Pichon. 1986. Cycle of the vasoactive intestinal peptide and its binding site in a human adenocarcinoma cell line (HT 29). Eur. J. Biochem. 156: 631–636. 10.1111/j.1432-1033.1986.tb09624.x CASPubMedWeb of Science®Google Scholar 44 Svoboda, M., P. De Neef, M. Tastenoy & J. Christophe. 1988. Molecular characteristics and evidence for internalization of vasoactive-intestinal-peptide (VIP) receptors in the tumoral rat-pancreatic acinar cell line AR 4–2 J. Eur. J. Biochem. 176: 707–713. 10.1111/j.1432-1033.1988.tb14334.x CASPubMedWeb of Science®Google Scholar 45 Anteunis, A., A. Astesano, B. Portha, G. Hejblum & G. Rosselin. 1989. Ultrastructural analysis of VIP internalization in rat β and acinar cells in situ. Am. J. Physiol. 256 (Gastrointest. Liver Physiol. 19): G689–G697. PubMedWeb of Science®Google Scholar 46 Omary, M. B. & M. F. Kagnoff. 1987. Identification of nuclear receptors for VIP on a human colonic adenocarcinoma cell line Science 238: 1578–1581. PubMedWeb of Science®Google Scholar 47 Schachter, M., K. E. J. Dickinson, C. M. Miles & P. S. Sever. 1986. Characterisation of a high-affinity VIP receptor in human lung parenchyma. FEBS Lett. 199: 125–129. 10.1016/0014-5793(86)81237-6 CASPubMedWeb of Science®Google Scholar 48 Paui, S. & S. I. Said. 1987. Characterization of receptors for vasoactive intestinal peptide solubilized from the lung. J. Biol. Chem. 261(1): 158–162. Google Scholar 49 Provow, S. & G. Veliçelebi. 1987. Characterization and solubilization of vasoactive intestinal peptide receptors from rat lung membranes. Endocrinology 120: 2442–2452. 10.1210/endo-120-6-2442 CASPubMedWeb of Science®Google Scholar 50 Robberecht, P., M. Waelbroeck, P. De Neef, J. C. Camus, D. H. Coy & J. Christophe. 1987. Pharmacological characterization of VIP receptors in human lung membranes. 9: 339–345. Web of Science®Google Scholar 51 Patthi, S., M. Akong & G. Veliçelebi. 1987. Hydrodynamic characterization of vasoactive intestinal peptide receptors extracted from rat lung membranes in Triton X-100 and n-Octyl-β-D-glucopyranoside. J. Biol. Chem. 262: 15740–15745. CASPubMedWeb of Science®Google Scholar 52 Patihi, S., S. Simerson & G. Veliçelebi. 1988. Solubilization of rat lung vasoactive intestinal peptide receptors in the active state. Characterization of the binding properties and comparison with membrane-bound receptors. J. Biol. Chem. 263: 19363–19369. PubMedWeb of Science®Google Scholar 53 Couvineau, A., T. Voisin, L. Guijarro & M. Laburthe. 1990. Purification of vasoactive intestinal peptide receptor from porcine liver by a newly designed one-step affinity chromatography. J. Biol. Chem. 265: 13386–13390. CASPubMedWeb of Science®Google Scholar 54 Coburn, R. F. & T. Tomita. 1973. Evidence for nonadrenergic inhibitory nerves in guinea pig trachealis muscle. Am. J. Physiol. 224: 1072–1080. 10.1152/ajplegacy.1973.224.5.1072 CASPubMedWeb of Science®Google Scholar 55 Richardson, J. & J. Beland. 1976. Nonadrenergic inhibitory nervous system in human airways. J. Appl. Physiol. 41: 764–771. PubMedWeb of Science®Google Scholar 56 Giachetti, A., S. I. Said, R. C. Reynolds & F. C. Koniges. 1977. Vasoactive intestinal polypeptide (VIP) in brain: localization in, and release from, isolated nerve terminals. Proc. Natl. Acad. Sci. USA 74: 3424–3428. 10.1073/pnas.74.8.3424 CASPubMedWeb of Science®Google Scholar 57 Said, S. I., A. Giachetti & S. Nicosia. 1980. VIP: possible functions as a neural peptide. In Neural Peptides and Neuronal Communication. E. Costa & M. Trabucchi, Eds.: 75–82. Raven Press. New York . Google Scholar 58 Lundberg, J. M., T. Hökfelt, G. Nilsson, L. Terenius, J. Rehfeld, R. Edle & S. I. Said. 1978. Peptide neurons in the vagus, splanchnic, and sciatic nerves. Acta Physiol. Scand. 104: 499–501. 10.1111/j.1748-1716.1978.tb06307.x PubMedWeb of Science®Google Scholar 59 Irvin, C. G., R. Boileau, J. Tremblay, R. R. Martin & P. T. Macklem. 1980. Bronchodilation: noncholinergic, nonadrenergic mediation demonstrated in vivo in the cat. Science 207: 791–792. 10.1126/science.7352292 CASPubMedWeb of Science®Google Scholar 60 Cameron, A. C., C. F. Johnson, C. T. Kirkpatrick & M. C. A. Kirkpatrick. 1983. The quest for the inhibitory neurotransmitter in bovine tracheal smooth muscle. Q. J. Exp. Physiol. 68: 413–426. 10.1113/expphysiol.1983.sp002735 CASPubMedWeb of Science®Google Scholar 61 Venugopalan, G. S., S. I. Said & J. M. Drazen. 1984. Effect of vasoactive intestinal peptide on vagally mediated tracheal pouch relaxation. Respir. Physiol. 56: 205–216. 10.1016/0034-5687(84)90104-X CASPubMedWeb of Science®Google Scholar 62 Matsuzaki, Y., Y. Hamasaki & S. I. Said. 1980. Vasoactive intestinal peptide: a possible transmitter of non-adrenergic relaxation of guinea pig airways. Science 210: 1252–1253. 10.1126/science.6254154 CASPubMedWeb of Science®Google Scholar 63 Russell, J. A. 1980. Nonadrenergic inhibitory innervation of canine airways. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 48: 16–22. CASPubMedWeb of Science®Google Scholar 64 Karlsson, J. A. & C. G. A. Persson. 1983. Evidence against vasoactive intestinal polypeptide (VIP) as a dilator and in favour of substance P as a constrictor in airway neurogenic response. Br. J. Pharmacol. 79: 634–636. 10.1111/j.1476-5381.1983.tb09999.x CASPubMedWeb of Science®Google Scholar 65 Mutt, V. & S. I. Said. 1974. Structure of the porcine vasoactive intestinal octacosapeptide: the amino acid sequence: use of kallikrein in its determination. Eur. J. Biochem. 42: 581–589. 10.1111/j.1432-1033.1974.tb03373.x CASPubMedWeb of Science®Google Scholar 66 Diamond, L. & R. J. Altiere. 1988. Airway nonadrenergic noncholinergic inhibitory nervous system. In The Airways: Neural Control in Health and Disease. M. A. Kaliner & P. Barnes, Eds.: 343–394. In Lung Biology in Health and Disease. C. Lenfant, Exec. Ed. Marcel Dekker. New York. Google Scholar 67 Richardson, J. B. 1979. Nerve supply to the lungs. Am. Rev. Respir. Dis. 119: 785–802. CASPubMedWeb of Science®Google Scholar 68 Ollerenshaw, S., D. Jarvis, A. Woolcock, C. Sullivan & T. Scheibner. 1989. Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma. N. Engl. J. Med. 320: 1244–1248. 10.1056/NEJM198905113201904 CASPubMedWeb of Science®Google Scholar 69 Paul, S., D. J. Volle, C. M. Beach, D. R. Johnson, M. J. Powell & R. J. Masset. 1989. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science 244: 1158–1162. 10.1126/science.2727702 CASPubMedWeb of Science®Google Scholar 70 Saga, T. & S. I. Said. 1984. Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans. Assoc. Am. Physicians 9: 304–310. Google Scholar 71 Nathanson, I., J. H. Widdicombe & P. J. Barnes. 1983. Effect of vasoactive intestinal peptide on ion transport across dog tracheal epithelium. J. Appl. Physiol. 55: 1844–1848. 10.1152/jappl.1983.55.6.1844 CASPubMedWeb of Science®Google Scholar 72 Undem, B. J., E. C. Dick & C. K. Buckner. 1983. Inhibition by vasoactive intestinal peptide of antigen-induced histamine release from guinea-pig minced lung. Eur. J. Pharmacol. 88: 247–249. 10.1016/0014-2999(83)90012-2 CASPubMedWeb of Science®Google Scholar 73 Said, S. I. 1991. VIP as a modulator of lung inflammation and airway constriction. Am. Rev. Respir. Dis. 143: S22–S24. 10.1164/ajrccm/143.3_Pt_2.S22 CASPubMedWeb of Science®Google Scholar 74 Barnes, P. J. 1989. A new approach to the treatment of asthma. N. Engl. J. Med. 321: 1517–1527. 10.1056/NEJM198911303212206 PubMedWeb of Science®Google Scholar 75 Ottaway, C. A. 1987. Selective effects of vasoactive intestinal peptide on the mitogenic response of murine T cells. Immunology 62: 291–297. CASPubMedWeb of Science®Google Scholar 76 Litwin, D. K., W. D. Claypool, E. ÖNal, H. D. Foda & S. I. Said. 1989. Vasoactive intestinal polypeptide inhibits rat alveolar macrophage phagocytosis. Am. Rev. Respir. Dis. 139: A158. Google Scholar 77 Litwin, D. K., S. I. Said, D. W. Carley & W. D. Claypool. 1990. Vasoactive intestinal polypeptide inhibits rat alveolar macrophage chemotaxis. Am. Rev. Respir. Dis. 141: A645. Google Scholar 78 Berisha, H., H. Foda, H. Sakakibara, M. Trotz, H. Pakbaz & S. I. Said. 1990. Am. J. Physiol. 259 (Lung Cell. Mol. Physiol. 3): L151–Ll55. CASPubMedWeb of Science®Google Scholar 79 Trotz, M. E., J. Luis & S. I. Said. 1990. Vasoactive intestinal peptide (VIP) inhibits phospholipase A2: a mechanism of anti-inflammatory activity. FASEB J. 4: A1124. Google Scholar 80 Misra, B. R. & H. P. Misra. 1990. Vasoactive intestinal peptide, a singlet oxygen quencher. J. Biol. Chem. 265: 15371–15374. CASPubMedWeb of Science®Google Scholar 81 Brenneman, D. E. & L. E. Eiden. 1986. Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc. Natl. Acad. Sci. USA 83: 1159–1162. 10.1073/pnas.83.4.1159 CASPubMedWeb of Science®Google Scholar 82 Pincus, D. W., E. M. DiCicco-Bloom & I. B. Black. 1990. Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuro-blasts. Nature 343: 564–567. 10.1038/343564a0 CASPubMedWeb of Science®Google Scholar 83 Brenneman, D. E., G. L. Westbrook, S. P. Fitzgerald, D. L. Ennist, K. L. Elkins, M. R. Ruff & C. B. Pert. 1988. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 335: 639–642. 10.1038/335639a0 CASPubMedWeb of Science®Google Scholar 84 Laitinen, L. A., M. Heino, A. Laitinen, T. Kava & T. Haahtela. 1985. Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am. Rev. Respir. Dis. 131: 599–606. 10.1164/arrd.1985.131.4.599 CASPubMedWeb of Science®Google Scholar 85 Frigas, E. & G. J. Gleich. 1986. The eosinophil and the pathophysiology of asthma. J. Allergy Clin. Immunol. 77: 527–537. 10.1016/0091-6749(86)90341-6 CASPubMedWeb of Science®Google Scholar 86 Palmer, J. B. D., F. M. C. Cuss, J. B. Warren, M. Blank, S. R. Bloom & P. J. Barnes. 1986. Effect of infused vasoactive intestinal peptide on airway function in normal subjects. Thorax 41: 663–666. 10.1136/thx.41.9.663 CASPubMedWeb of Science®Google Scholar 87 Morice, A., R. J. Unwin & P. S. Sever. 1983. Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects. Lancet 2: 1225–1227. 10.1016/S0140-6736(83)91272-2 PubMedWeb of Science®Google Scholar 88 Barnes, P. J. & C. M. S. Dixon. 1984. The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans. Am. Rev. Respir. Dis. 130: 162–166. CASPubMedWeb of Science®Google Scholar 89 Bundgaard, A., S. D. Enehjelm & S. Aggestrup. 1983. Pretreatment of exerciseinduced asthma with inhaled vasoactive intestinal peptide (VIP). Eur. J. Respir. Dis. 64(Suppl. 128): 427–429. Web of Science®Google Scholar 90 Caughey, G. H., F. Leidig, N. F. Viro & J. A. Nadel. 1988. Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J. Pharmacol. Exp. Ther. 244: 133–137. CASPubMedWeb of Science®Google Scholar 91 Franconi, G., P. D. Graf, S. C. Lazarus, J. A. Nadel & G. H. Caughey. 1989. Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret. J. Pharmacol. Exp. Ther. 248: 947–951. CASPubMedWeb of Science®Google Scholar 92 Goetzl, E. J., S. P. Sreedharan, C. W. Turck, R. Bridenbaugh & B. Malfroy. 1989. Preferential cleavage of amino- and carboxyl-terminal oligopeptides from vasoactive intestinal polypeptide by human recombinant enkephalinase (neutral endopeptidase, EC 3.4.24.11). Biochem. Biophys. Res. Commun. 158: 850–854. PubMedWeb of Science®Google Scholar 93 Liu, L. W., T. Sata, E. Kubota, S. Paul & S. I. Said. 1987. Airway relaxant effect of vasoactive intestinal peptide (VIP); selective potentiation by phosphoramidon, an enkephalinase inhibitor. Am. Rev. Respir. Dis. 135 (Suppl.): A86. Google Scholar 94 Tam, E. K. & G. H. Caughey. 1990. Degradation of airway neuropeptides by human lung tryptase. Am. J. Respir. Cell Mol. Biol. 3: 27–32. 10.1165/ajrcmb/3.1.27 CASPubMedWeb of Science®Google Scholar 95 Robberecht, P., A. Vandermeers, M.-C. Vandermeers-Piret, P. Gourlet, A. Cauvin, P. De Neef & J. Christophe. 1988. Helodermin-like peptides. Am. N.Y. Acad. Sci. 527: 186–203. 10.1111/j.1749-6632.1988.tb26981.x CASPubMedWeb of Science®Google Scholar 96 Foda, H. D. & S. I. Said. 1989. Helodermin, a C-terminally extended VIP-like peptide, evokes long-lasting tracheal relaxation. Biomed. Res. 10: 107–110. CASWeb of Science®Google Scholar 97 Bolin, D. R., J. M. Cottrell, D. C. Fry, V. S. Madison, N. O'Neill, R. Garippa & M. O'Donnell. 1989. Synthesis, biological activity, and conformation of analogs of vasoactive intestinal peptide. Regul. Pept. 26: 145. 10.1016/0167-0115(89)90017-7 Web of Science®Google Scholar Citing Literature Volume629, Issue1Advances in the Understanding andTreatment of AsthmaJuly 1991Pages 305-318 ReferencesRelatedInformation